Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new Medium article from our Department explores how optogenetics has transformed neuroscientific research and opened new possibilities for the treatment of brain disorders, and sheds light on the series of early research work undertaken by Professor Gero Miesenböck and his team to evolve this breakthrough technology.

Image: Gero Miesenböck

On the afternoon of 12 June 1999, a Saturday, Gero Miesenböck returned to his apartment in Manhattan from a long walk after lunch, ready to open a book he had been absorbed in, Independence Day by Richard Ford. “As I was reaching for the book, drifting from the real world into Ford’s fictional New Jersey, there was the idea of optogenetic control. I knew instantly that I was on to something. My wife remembers my excitement as I tried to explain the concept to her, and especially the terrible hangover nearly two years later when my postdoc and I celebrated that we had got it to work.”

That Manhattan moment launched a series of now classical studies that made Miesenböck the first scientist to modify nerve cells genetically so that their activity could be controlled by light. This breakthrough technology, called optogenetics, has transformed neuroscientific research and opened new possibilities for the treatment of brain disorders. By providing the means to control neural signals with high precision, optogenetics has raised neurobiology’s standards of proof. It has shed light, literally and figuratively, on virtually every brain function: sensation and movement, motivation and learning, sleep and waking, communication and decision-making.

Read more (Medium website)

Similar stories

REF 2021 results

Oxford Parkinson’s Disease Centre awarded £3.8 million to reveal the role of calcium in Parkinson’s

A collaborative research team led by the Oxford Parkinson’s Disease Centre (OPDC) has been awarded a £3.8 million Wellcome Trust Collaborative Award to study the function of calcium in dopamine neurons, and how this is plays a role in Parkinson’s. Their research will help explain how and why dopamine neurons are vulnerable in the disease and look at how they may be preserved.

The effect of nuclear pH on cardiac gene expression

Research led by Dr Alzbeta Hulikova and Professor Pawel Swietach has, for the first time, described the potential regulation of nuclear acid-base chemistry in neonatal and adult cardiomyocytes, and explained its relevance in the context of heart physiology and pathology.

A role of sleep in tinnitus identified for the first time

Phantom percepts, such as subjective tinnitus, are driven by fundamental changes in spontaneous brain activity. Sleep is a natural example of major shifts in spontaneous brain activity and perceptual state, suggesting an interaction between sleep and tinnitus that has so far been little considered. In a new collaborative review article from DPAG’s auditory and sleep neuroscientists, tinnitus and sleep research is brought together for the first time, and, in conclusion, they propose a fundamental relationship between natural brain dynamics and the expression and pathogenesis of tinnitus.

An unexpected role for the cell’s largest membrane network

A new Klemm Lab-led paper has uncovered a new mechanism involving the endoplasmic reticulum that is critical to the organisation and position of the microtubule (MT) cytoskeleton, which ultimately dictates the shape and function of our body’s cells.